Startseite>>Signaling Pathways>> Chromatin/Epigenetics>> Epigenetic Reader Domain>>Menin-MLL inhibitor 20

Menin-MLL inhibitor 20

Katalog-Nr.GC63538

Menin-MLL-Inhibitor 20 ist ein irreversibler Menin-MLL-Interaktionsinhibitor mit AntitumoraktivitÄten (WO2020142557A1, Intermediat 6).

Products are for research use only. Not for human use. We do not sell to patients.

Menin-MLL inhibitor 20 Chemische Struktur

Cas No.: 2448173-47-3

Größe Preis Lagerbestand Menge
5 mg
153,00 $
Auf Lager
10 mg
252,00 $
Auf Lager
25 mg
504,00 $
Auf Lager
50 mg
819,00 $
Auf Lager
100 mg
1.305,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6)[1].

The Histone-lysine N-methyltransferase 2 (KMT2) family of proteins, which currently consists of at least 5 members, methylate ly sine 4 on the histone H3 tails at important regulatory regions in the genome and thereby impart crucial functions through the modulation of chromatin structures and DNA accessibility. These enzymes are known to play an important role in the regulation of gene expression during early development and hematopoiesis. The human KMT2 family was initially named the mixed-lineage leukaemia (MLL) family, owing to the role of the first-found member in this disease[1].

[1]. Thomas Butler, et al. Irreversible inhibitors of menin-mll interaction. WO2020142557A1.

Bewertungen

Review for Menin-MLL inhibitor 20

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Menin-MLL inhibitor 20

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.